D. L. Jiménez

Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?

L. C. Guerra, D. L. Jiménez, J. Chozas, 2018 .

VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia.

L. Pérez de Isla, R. González-Sarmiento, J. Martín-Vallejo, 2019, Atherosclerosis.

The mechanism of action of sodium-glucose co-transporter 2 inhibitors is similar to carbonic anhydrase inhibitors.

D. L. Jiménez, R. G. Huelgas, José Pablo Miramontes González, 2018 .

GLP-1 and the renin-angiotensin-aldosterone system.

J. P. Miramontes González, D. L. Jiménez, M. C. Babkowski, 2019, The lancet. Diabetes & endocrinology.

Bleeding risk assessment for stroke patients on antithrombotic therapy

L. Castilla-Guerra, M. Fernández-Moreno, Juan Manuel de la Vega-Sánchez, 2019, Clínica e Investigación en Arteriosclerosis (English Edition).

Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors

L. P. Isla, A. Romero, D. L. Jiménez, 2019, Revista Clínica Española (English Edition).

Reply to ‘Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes’ by Yoshimoto et al.

D. L. Jiménez, J. Chozas, R. Temprano, 2018 .

Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis.

A. Montoro, L. C. Guerra, D. L. Jiménez, 2019 .

Epiploic appendagitis as unusual cause of acute abdominal pain: Clinical and radiologic features of 7 patients

C. B. López, D. L. Jiménez, E. Lado, 2019 .